<DOC>
	<DOCNO>NCT02780869</DOCNO>
	<brief_summary>The purpose prospective , randomize , control study evaluate safety efficacy new hemostatic device ( HEMOBLAST™ Bellows ) compare control device , absorbable gelatin sponge USP thrombin .</brief_summary>
	<brief_title>HEMOBLAST Pivotal Clinical Investigation</brief_title>
	<detailed_description />
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Gelatin Sponge , Absorbable</mesh_term>
	<criteria>• Subject undergo elective open cardiothoracic , abdominal , orthopedic low extremity surgery ; Subject authorize legal representative willing able give prior write informed consent investigation participation ; Subject undergo cardiothoracic surgery allergic protamine ; Subject 21 year age old . • Subject undergoing laparoscopic , thoracoscopic , robotic surgical procedure ; Subject undergo neurologic surgical procedure ; Subject undergo spinal surgical procedure ; Subject undergo emergency surgical procedure ; Subject pregnant , plan become pregnant followup period , actively breastfeed ; Subject clinically significant coagulation disorder disease , define platelet count &lt; 100,000 per microliter International Normalized Ratio &gt; 1.5 within 4 week surgery ; Subject receive intravenous heparin within 12 hour surgery oral Coumadin within 2 day surgery ; Subject receive antiplatelet medication within 5 day prior surgery ; Subject undergo abdominal orthopedic low extremity surgery receive aspirin within 7 day prior surgery ; Subject active suspect infection surgical site ; Subject plan receive organ transplantation ; Subject know sensitivity allergy bovine and/or porcine substance ( ) component ( ) hemostatic agent ; Subject ASA classification 5 ; Subject life expectancy le 3 month ; Subject know psychiatric disorder , opinion Principal Investigator , would preclude subject complete clinical study ; Subject document severe congenital acquire immunodeficiency ; Subject religious objection porcine , bovine , human component ; Subject investigational control device use site valve replacement repair ; Subject investigational control device use site synthetic graft patch implant ; Subject currently participate participate another clinical trial within past 30 day receiving/has receive investigational drug , device , biologic agent ; Subject appropriate inclusion clinical trial , per medical opinion Principal Investigator . Intraoperative Eligibility Criteria : Subject active suspect infection surgical site ; Subject undergo cardiothoracic surgery anticoagulation must anticoagulation reverse prior target bleed site ( TBS ) identification treatment ; Subject Investigator able identify TBS applicable conventional mean hemostasis ineffective impractical ; Subject TBS SBSS score 1 , 2 , 3 .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>